Chimeric antigen receptor T-cell therapy for aggressive B-cell lymphomas

被引：0
作者：
Hu, Bei [1 ]
Korsos, Victoria [2 ]
Palomba, M. Lia [2 ,3 ]
机构：
[1] Wake Forest Sch Med, Atrium Hlth Levine Canc Inst, Dept Hematol Oncol & Blood Disorders, Charlotte, NC 28202 USA
[2] Mem Sloan Kettering Canc Ctr, Dept Med, Cellular Therapy Serv, New York, NY USA
[3] Mem Sloan Kettering Canc Ctr, Dept Med, Lymphoma Serv, New York, NY USA
来源：
FRONTIERS IN ONCOLOGY | 2024年 / 14卷
关键词：
chimeric antigen receptor T cell therapy (CAR T cell therapy); diffuse large B cell lymphoma (DLBCL); high grade B cell lymphoma; mantle cell lymphoma (MCL); relapsed and refractory lymphoma; CENTRAL-NERVOUS-SYSTEM; AXICABTAGENE CILOLEUCEL; COST-EFFECTIVENESS; BREXUCABTAGENE AUTOLEUCEL; PREDICTIVE FACTORS; OUTCOMES; MULTICENTER; INFLAMMATION; PERSISTENCE; IBRUTINIB;
D O I：
10.3389/fonc.2024.1394057
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Chimeric antigen receptor (CAR) T-cell therapy is a revolutionary approach in the treatment of lymphoma. This review article provides an overview of the four FDA-approved CAR T-cell products for aggressive B-cell lymphoma, including diffuse large B-cell lymphoma and mantle cell lymphoma, highlighting their efficacy and toxicity as well as discussing future directions.
引用
收藏
页数：13
相关论文
共 102 条
  • [1] Two-year follow-up of lisocabtagene maraleucel in relapsed or refractory large B-cell lymphoma in TRANSCEND NHL 001
    Abramson, Jeremy S.
    Palomba, M. Lia
    Gordon, Leo I.
    Lunning, Matthew
    Wang, Michael
    Arnason, Jon
    Purev, Enkhtsetseg
    Maloney, David G.
    Andreadis, Charalambos
    Sehgal, Alison
    Solomon, Scott R.
    Ghosh, Nilanjan
    Dehner, Christine
    Kim, Yeonhee
    Ogasawara, Ken
    Kostic, Ana
    Siddiqi, Tanya
    [J]. BLOOD, 2024, 143 (05) : 404 - 416
  • [2] Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study
    Abramson, Jeremy S.
    Palomba, M. Lia
    Gordon, Leo I.
    Lunning, Matthew A.
    Wang, Michael
    Arnason, Jon
    Mehta, Amitkumar
    Purev, Enkhtsetseg
    Maloney, David G.
    Andreadis, Charalambos
    Sehgal, Alison
    Solomon, Scott R.
    Ghosh, Nilanjan
    Albertson, Tina M.
    Garcia, Jacob
    Kostic, Ana
    Mallaney, Mary
    Ogasawara, Ken
    Newhall, Kathryn
    Kim, Yeonhee
    Li, Daniel
    Siddiqi, Tanya
    [J]. LANCET, 2020, 396 (10254) : 839 - 852
  • [3] CAR T-cell therapy for secondary CNS DLBCL
    Ahmed, Gulrayz
    Hamadani, Mehdi
    Shah, Nirav N.
    [J]. BLOOD ADVANCES, 2021, 5 (24) : 5626 - 5630
  • [4] CAR T-cell therapy in primary central nervous system lymphoma: the clinical experience of the French LOC network
    Alcantara, Marion
    Houillier, Caroline
    Blonski, Marie
    Rubio, Marie-Therese
    Willems, Lise
    Rascalou, Agathe Waultier
    Le Garff-Tavernier, Magali
    Maloum, Karim
    Bravetti, Clotilde
    Souchet, Laetitia
    Roos-Weil, Damien
    Morel, Veronique
    Uzunov, Madalina
    Metz, Carole
    Dhib-Charfi, Meriem
    Nguyen, Stephanie
    Shor, Natalia
    Psimaras, Dimitri
    Weiss, Nicolas
    Jacque, Nathalie
    Solorzano, Silvia
    Gauthier, Nicolas
    Le Cann, Marie
    Norol, Francoise
    Soussain, Carole
    Choquet, Sylvain
    [J]. BLOOD, 2022, 139 (05) : 792 - 796
  • [5] Baguet C, 2024, BLOOD ADV, V8, P337, DOI 10.1182/bloodadvances.2023011992
  • [6] Cost-Effectiveness of Brexucabtagene Autoleucel versus Best Supportive Care for the Treatment of Relapsed/Refractory Mantle Cell Lymphoma following Treatment with a Bruton's Tyrosine Kinase Inhibitor in Canada
    Ball, Graeme
    Lemieux, Christopher
    Cameron, David
    Seftel, Matthew D.
    [J]. CURRENT ONCOLOGY, 2022, 29 (03) : 2021 - 2045
  • [7] Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma
    Bishop, M. R.
    Dickinson, M.
    Purtill, D.
    Barba, P.
    Santoro, A.
    Hamad, N.
    Kato, K.
    Sureda, A.
    Greil, R.
    Thieblemont, C.
    Morschhauser, F.
    Janz, M.
    Flinn, I
    Rabitsch, W.
    Kwong, Y-L
    Kersten, M. J.
    Minnema, M. C.
    Holte, H.
    Chan, E. H. L.
    Martinez-Lopez, J.
    Mueller, A. M. S.
    Maziarz, R. T.
    McGuirk, J. P.
    Bachy, E.
    Le Gouill, S.
    Dreyling, M.
    Harigae, H.
    Bond, D.
    Andreadis, C.
    McSweeney, P.
    Kharfan-Dabaja, M.
    Newsome, S.
    Degtyarev, E.
    Awasthi, R.
    del Corral, C.
    Andreola, G.
    Masood, A.
    Schuster, S. J.
    Jaeger, U.
    Borchmann, P.
    Westin, J. R.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2022, 386 (07) : 629 - 639
  • [8] Successful treatment by CAR T-cells in multi-refractory mantle cell lymphoma with central nervous system involvement
    Caillet, Adrien
    Houillier, Caroline
    Sourdeau, Elise
    Gazzano, Marianne
    Uzunov, Madalina
    Friser, Valerie
    Ribeiro, Monica
    Nicelli, Lucia
    Azar, Nabih
    Baron, Marine
    Phina-Ziebin, Xavier
    Choquet, Sylvain
    Roos-Weil, Damien
    [J]. ANNALS OF HEMATOLOGY, 2023, 102 (11) : 3295 - 3297
  • [9] Patients with mantle cell lymphoma failing ibrutinib are unlikely to respond to salvage chemotherapy and have poor outcomes
    Cheah, C. Y.
    Chihara, D.
    Romaguera, J. E.
    Fowler, N. H.
    Seymour, J. F.
    Hagemeister, F. B.
    Champlin, R. E.
    Wang, M. L.
    [J]. ANNALS OF ONCOLOGY, 2015, 26 (06) : 1175 - 1179
  • [10] Cost-effectiveness of Axicabtagene Ciloleucel and Tisagenlecleucel as Second-line or Later Therapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
    Choe, Jee H.
    Abdel-Azim, Hisham
    Padula, William, V
    Abou-El-Enein, Mohamed
    [J]. JAMA NETWORK OPEN, 2022, 5 (12)
12345678910